- Home
- MYSZ vs APVO Comparison
MYSZ vs APVO Comparison
Compare MYSZ & APVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MYSZ
- APVO
- Stock Information
- Founded
- MYSZ 1999
- APVO 2016
- Country
- MYSZ Israel
- APVO United States
- Employees
- MYSZ N/A
- APVO N/A
- Industry
- MYSZ Computer Software: Prepackaged Software
- APVO Biotechnology: Pharmaceutical Preparations
- Sector
- MYSZ Technology
- APVO Health Care
- Exchange
- MYSZ Nasdaq
- APVO Nasdaq
- Market Cap
- MYSZ 4.0M
- APVO 4.1M
- IPO Year
- MYSZ N/A
- APVO N/A
- Fundamental
- Price
- MYSZ $1.27
- APVO $4.95
- Analyst Decision
- MYSZ Strong Buy
- APVO Strong Buy
- Analyst Count
- MYSZ 1
- APVO 1
- Target Price
- MYSZ $3.00
- APVO $5,920.00
- AVG Volume (30 Days)
- MYSZ 119.6K
- APVO 393.8K
- Earning Date
- MYSZ 05-15-2025
- APVO 05-14-2025
- Dividend Yield
- MYSZ N/A
- APVO N/A
- EPS Growth
- MYSZ N/A
- APVO N/A
- EPS
- MYSZ N/A
- APVO N/A
- Revenue
- MYSZ $6,752,000.00
- APVO N/A
- Revenue This Year
- MYSZ $29.71
- APVO N/A
- Revenue Next Year
- MYSZ N/A
- APVO N/A
- P/E Ratio
- MYSZ N/A
- APVO N/A
- Revenue Growth
- MYSZ N/A
- APVO N/A
- 52 Week Low
- MYSZ $1.01
- APVO $4.30
- 52 Week High
- MYSZ $9.40
- APVO $658.60
- Technical
- Relative Strength Index (RSI)
- MYSZ 51.60
- APVO 28.32
- Support Level
- MYSZ $1.18
- APVO $4.30
- Resistance Level
- MYSZ $1.34
- APVO $5.18
- Average True Range (ATR)
- MYSZ 0.09
- APVO 1.22
- MACD
- MYSZ 0.01
- APVO 0.72
- Stochastic Oscillator
- MYSZ 65.22
- APVO 6.47
About MYSZ My Size Inc.
My Size Inc is a USA-based technology company that focuses on the development of an application that assists the consumer to accurately take the measurements of his or her own body to fit clothing without the need to try them on using a smartphone. The purpose of the company's business is to simplify the process of clothing acquisition through the Internet and to significantly reduce the rate of returns of clothing which were acquired through the internet and which are returned to the stores because of ill-fitting. The company generates its revenue through selling products to customers and licensing cloud-enabled software subscriptions, associated software maintenance, and support.
About APVO Aptevo Therapeutics Inc.
Aptevo Therapeutics Inc is a clinical-stage research and development biotechnology company focused on developing novel immunotherapeutic candidates for the treatment of different forms of cancer. Its clinical candidates are; ALG.APV-527, which targets co-stimulatory receptors and tumor antigens, and CD3xCD123, which is being developed as a potential treatment of frontline acute myelogenous leukemia. The company's preclinical candidates, APVO711, APVO0442, and APVO603, are being developed using the ADAPTIR modular protein technology platform. The company's versatile and robust ADAPTIR and ADAPTIR-FLEX platforms are designed to generate monospecific, bispecific, and multi-specific antibody candidates that are capable of enhancing the human immune system against cancer cells.